✦ LIBER ✦

Time to include high-risk early ovarian cancer in randomized phase III trials of advanced ovarian cancer

✍ Scribed by Ignace Vergote; Frederic Amant

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Prognostic impact of the time interval b

✍ S. Mahner; C. Eulenburg; A. Staehle; K. Wegscheider; A. Reuss; E. Pujade-Laurain 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 633 KB

Carbogen and nicotinamide in locally adv

✍ Peter J. Hoskin; Ana M. Rojas; Michele I. Saunders; S.M. Bentzen; K.J. Motohashi 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 226 KB

Developmental chemotherapy in advanced o

✍ Michael A Bookman 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 126 KB

Impact of age on outcome in patients wit

✍ Pauline Wimberger; Nils Lehmann; Rainer Kimmig; Alexander Burges; Werner Meier; 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 226 KB

Randomized phase III trial of chemoimmun

✍ David S. Alberts; Nancy Mason-Liddil; Robert V. O'Toole; Thomas M. Abbott; Richa 📂 Article 📅 1989 🏛 Elsevier Science 🌐 English ⚖ 593 KB

The Prophylactic Administration of Recom

✍ Maurie Markman 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 19 KB